Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00243932 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial of High Dose CoQ10 in ALS
A Phase 2 study, sponsored by Columbia University.
- Completed
- Registry status
- Phase 2
- Development phase
- 185
- Enrollment target
NCT00243932: Completed Phase 2 study, sponsored by Columbia University.
NCT00243932 is a Phase 2 study that has completed, run by Columbia University. The registered enrollment target is 185 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (39% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00243932, a Phase 2 study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 185 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy and preferred dose of CoQ10 in individuals with ALS for a possible future phase III study.
Primary Outcome
The ALSFRSr, a questionnaire-based scale assessing daily living function ranging from 48 (best score) to 0 (worst), was administered to the patient, or to a proxy if the patient could not communicate effectively. Decline was defined as ALSFRSr at baseline minus ALSFRSr at month 9. Thus a positive value indicates worsening.
Interventions
- DRUG Placebo
- DRUG coenzyme Q10
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2005-04 |
| Est. Completion | 2008-03 |
| Phase | Phase 2 |
What the finished NCT00243932 record still lists
NCT00243932 is an interventional study that assigns participants to a tested intervention. The registered 185 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (39% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00243932 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00243932 about?
NCT00243932 is a clinical study titled "Clinical Trial of High Dose CoQ10 in ALS". The purpose of this study is to determine the efficacy and preferred dose of CoQ10 in individuals with ALS for a possible future phase III study.
What is the current status of trial NCT00243932?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 185 participants. The study started on 2005-04. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00243932?
The interventions under investigation include: Placebo (DRUG), coenzyme Q10 (DRUG).
Who is sponsoring clinical trial NCT00243932?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00243932's enrollment target sits among peer trials
185 357th of 2000 higher than 1,641 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04041154 · 185 participants · NA
Behavioral and Neural Representations of Subjective Effort Cost
- NCT04484272 · 185 participants · NA
A Stress and Pain Self-management m-Health App for Adult Outpatients With Sickle Cell Disease
- NCT05020860 · 185 participants · Phase 2
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
- NCT05793541 · 185 participants · NA
Just-in-time Interventions for Reducing Short-term Suicide Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia